Drugs & Therapy Perspectives

, Volume 6, Issue 10, pp 1–5 | Cite as

Meropenem: a new carbapenem with potential for treating bacterial meningitis

New Drugs and Therapeutic


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995 50(1): 73–101PubMedCrossRefGoogle Scholar
  2. 2.
    British National Formulary No. 29. London: The Pharmaceutical Press. 1995Google Scholar
  3. 3.
    New Ethicals Compendium. Auckland: Adis International Ltd, 1994Google Scholar
  4. 4.
    Treatment of bacterial meningitis relies on early identification and antibacterial therapy. Drug Ther Perspect 1994 Nov 28; 4(11): 8–10CrossRefGoogle Scholar
  5. 5.
    Buckley MM, Brogden RN, Barradell LB, et al. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992; 44(3): 408–44PubMedCrossRefGoogle Scholar
  6. 6.
    Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995 Sep; 21: 544–50PubMedCrossRefGoogle Scholar
  7. 7.
    Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 179–89PubMedCrossRefGoogle Scholar
  8. 8.
    Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185–200CrossRefGoogle Scholar
  9. 9.
    Hamacher J, Vogel F, Lichey J. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients — a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 121–33PubMedCrossRefGoogle Scholar
  10. 10.
    Mouton JW, van den Anker. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995 Apr; 28(4): 275–86PubMedCrossRefGoogle Scholar
  11. 11.
    Sieger B, Geckler R. A comparison of meropenem and ceftazidime lus tobramycin in the treatment of hospital-acquired lower respiratory tract infections [abstract]. In: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1993: 236Google Scholar
  12. 12.
    Romanelli G, Cravarezza P, Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 109–19PubMedCrossRefGoogle Scholar
  13. 13.
    Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 207–23PubMedCrossRefGoogle Scholar
  14. 14.
    Mouton YJ, Beuscart C, Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 145–56PubMedCrossRefGoogle Scholar
  15. 15.
    Choice of antibacterial drugs. Mett lett 1994 Jun 24; 36(925): 53–60Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations